Repair Biotechnologies Granted Rare Disease Evidence Principles (RDEP) Eligibility by the FDA for REP-0003 in Homozygous Familial Hypercholesterolemia
AGC Biologics and Repair Biotechnologies Partner on Novel mRNA Therapeutic to Combat the Leading Cause of Human Mortality
Repair Biotechnologies Presents Preclinical Data at American Heart Association’s Scientific Sessions 2025 Showing Regression of Atherosclerotic Plaque with REP-0003 Treatment
Repair Biotechnologies Granted Rare Disease Evidence Principles (RDEP) Eligibility by the FDA for REP-0003 in Homozygous Familial Hypercholesterolemia Read more
AGC Biologics and Repair Biotechnologies Partner on Novel mRNA Therapeutic to Combat the Leading Cause of Human Mortality Read more
Repair Biotechnologies Presents Preclinical Data at American Heart Association’s Scientific Sessions 2025 Showing Regression of Atherosclerotic Plaque with REP-0003 Treatment Read more
Repair Biotechnologies Announces Appointment of Noted Endocrinologist Prof. Frederick J. Raal to Scientific Advisory Board Read more
Repair Biotechnologies Receives Orphan Drug Designation from the FDA for the Treatment of Homozygous Familial Hypercholesterolemia Read more
Repair Biotechnologies Announces Appointment of Noted Cardiologist Dr. Deepak L. Bhatt to Scientific Advisory Board Read more
